Sunshine Guojian Pharmaceutical Shanghai Co Ltd (688336) Fair Value & Analysis
Healthcare · CN · Market cap 42.9B CNY
Strengths
Risks
Fair value as of: Aug 13, 2026
From 25 valuation models · updated 12 days ago
Share price +1.8% over the past month.
A strong business, trading 44% below our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The rarer combination: high quality (82/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The model range is unusually wide (¥40.49 to ¥142.69). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ¥8.25 – ¥62.92 · fair‑value band ¥40.49 – ¥142.69 · the ¥43.46 price screens below the ¥78.27 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Sunshine Guojian Pharmaceutical Shanghai Co Ltd (688336) currently trades at ¥43.46, while our model-based Fair Value estimate is ¥78.27, implying the stock looks roughly 80.1% undervalued today. The Quality Score stands at 82/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Sunshine Guojian Pharmaceutical Shanghai Co Ltd generated revenue of 4.3B CNY at a net margin of 68.9%. Revenue grew 38.6% year over year. It earns a return on equity of 41.8%. The balance sheet holds a net cash position of 409M CNY. Fundamentals as of Aug 13, 2026
Our scenario range runs from ¥40.49 (bear case) to ¥142.69 (bull case); at ¥43.46, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 55% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -60% fair-value upside, at 80%, 688336 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: Growth Earnings (¥109.76) versus Dividend Discount (¥1.37). Highest evidence: Residual Income (76).
Notify me when 688336 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 80 · Market factors (momentum, volatility) 52
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs.
Full company description
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. The company was founded in 2002 and is based in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sunshine Guojian Pharmaceutical Shanghai Co Ltd reported revenue of ¥4.2B in FY2025 versus ¥929M in FY2021, a compound +45.8%/yr. Reported net income was ¥2.9B in FY2025, compounding +257.2%/yr from FY2021.
of which total revenue +10.5 pp · buybacks/dilution −2.3 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch 688336: get an alert when its fair value changes →
Peer Group
Biotechnology · 634 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $525.73 | $278.78 | -47% |
| Regeneron Pharmaceuticals, Inc REGN | $797.99 | $594.40 | -26% |
| argenx SE ARGX | €877.60 | €292.84 | -67% |
| Samsung Biologics Co 207940 | 1,549,000 KRW | 1,055,793 KRW | -32% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | -77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | -60% |
| Celltrion, Inc 068270 | 202,000 KRW | 74,519 KRW | -63% |
| BeOne Medicines AG ONC | $362.51 | $111.35 | -69% |
| Moderna, Inc MRNA | $63.67 | $12.77 | -80% |
| BioNTech SE 22UA | €80.60 | €52.92 | -34% |
Compare Sunshine Guojian Pharmaceutical Shanghai Co Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Sunshine Guojian Pharmaceutical Shanghai Co Ltd (688336) overvalued or undervalued?
What is the fair value of 688336?
What is the quality score of 688336?
What is the revenue of Sunshine Guojian Pharmaceutical Shanghai Co Ltd (688336)?
What is the net profit margin of 688336?
Does Sunshine Guojian Pharmaceutical Shanghai Co Ltd pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Sunshine Guojian Pharmaceutical Shanghai Co Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.